Tenascin-C Enhances Pancreatic Cancer Cell Growth and Motility and Affects Cell Adhesion through Activation of the Integrin Pathway

Igor Paron1,2, Sonja Berchtold1,2, Julia Vörös1, Madhavi Shamarla1, Mert Erkan3, Heinz Höfler1,2, Irene Esposito1,2*

1 Institute of Pathology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany, 2 Institute of Pathology, Technische Universität München, Munich, Germany, 3 Department of General Surgery, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

Abstract

Background: Pancreatic cancer (PDAC) is characterized by an abundant fibrous tissue rich in Tenascin-C (TNC), a large ECM glycoprotein mainly synthesized by pancreatic stellate cells (PSCs). In human pancreatic tissues, TNC expression increases in the progression from low-grade precursor lesions to invasive cancer. Aim of this study was the functional characterization of the effects of TNC on biologic relevant properties of pancreatic cancer cells.

Methods: Proliferation, migration and adhesion assays were performed on pancreatic cancer cell lines treated with TNC or grown on a TNC-rich matrix. Stable transfectants expressing the large TNC splice variant were generated to test the effects of endogenous TNC. TNC-dependent integrin signaling was investigated by immunoblotting, immunofluorescence and pharmacological inhibition.

Results: Endogenous TNC promoted pancreatic cancer cell growth and migration. A TNC-rich matrix also enhanced migration as well as the adhesion to the uncoated growth surface of poorly differentiated cell lines. In contrast, adhesion to fibronectin was significantly decreased in the presence of TNC. The effects of TNC on cell adhesion were paralleled by changes in the activation state of paxillin and Akt.

Conclusion: TNC affects proliferation, migration and adhesion of poorly differentiated pancreatic cancer cell lines and might therefore play a role in PDAC spreading and metastasis in vivo.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) represents 85–90% of all pancreatic neoplasms. In 2010 43,140 people in the US were estimated to be diagnosed with pancreatic cancer and 36,800 to die of this lethal disease, making PDAC the fourth most common cause of tumor-related mortality in spite of an incidence of only 3% of total cases [1]. PDAC survival rates improved only marginally in the last 30 years and PDAC patients still have a very poor prognosis, with an overall 5-year survival rate below 5% and a median survival rate that ranges from 2 months in patients with metastatic disease to 8 months in patients with non-metastatic disease at the time of diagnosis [2]. PDAC outcomes did not change much in the last several years mainly because of late diagnosis. PDAC as localized and regional disease is mainly asymptomatic and tools for an early detection are still missing. Once diagnosed, pancreatic cancer is often refractory to any chemotherapy and radiotherapy treatment, and many clinical trials have failed to demonstrate a significant improvement in overall survival during the last decade [3]. Therefore, a better comprehension of the mechanisms involved in PDAC development, maintenance and spreading is needed to develop new targeted therapies for the treatment of this nowadays still fatal disease.

A characteristic feature of PDAC is the so-called “desmoplastic” reaction, an abundant fibrous tissue that surrounds cancer cells and mainly consists of blood vessels and stromal cells spread in a scaffold of extracellular matrix (ECM). The development of the desmoplastic reaction is mainly due to pancreatic stellate cells (PSCs). PSCs are stromal cells which, after conversion from a quiescent into an active myofibroblast-like phenotype, secrete ECM proteins and matrix degrading enzymes, thus establishing an environment that strongly promotes cancer progression and, at the same time, imposes a barrier to drug delivery [4–7].

Tenascin-C (TNC) is a large ECM glycoprotein composed of six monomers linked at their N-termini with disulfide bonds to form a
Tenascin-C is mainly expressed during embryonic development. In adults, TNC has a limited pattern of expression (in the basement membrane of the skin, in the ducts of the salivary glands, in the colon mucosa and in the vessel walls of different organs), but protein levels rise dramatically under various physiological and pathological conditions, such as tissue remodeling, neovascularisation and inflammation [12,13]. Moreover, most solid tumors express high levels of TNC. TNC is able to influence cancer growth by affecting cell adhesion and motility in a way that can promote invasion and metastasis [14] and by influencing the cellular expression of tumor suppressor genes, oncogenes and genes involved in the maintenance of genome stability [15]. In the normal pancreas, TNC is expressed in the muscle wall of blood vessels and in the stromal tissue around the interlobular ducts. TNC expression is up-regulated in acute and chronic pancreatitis [16], and increases in the progression from low-grade precursor lesions (pancreatic intraepithelial neoplasia, PanIN) to PDAC [17]. In PDAC TNC is exclusively expressed in the stroma around the neoplastic glands [16,17]. Up-regulation of TNC in cancer progression seems to involve specifically the large splice variant, as the largest TNC transcript, corresponding to the unspliced form of TNC, is found in pancreatic cancer and in chronic pancreatitis, but not in the normal pancreas [17]. PSCs have been shown to be the main source of TNC in vivo, whereas PDAC cells did not show any expression of TNC either by immunohistochemistry or immunoblotting. However, low levels of TNC mRNA were found in pancreatic cancer cell lines by real-time quantitative PCR [17].

In this study, we performed an extensive analysis of the effects of exogenous TNC on pancreatic cancer cell functions and we investigated the effect of endogenous TNC overexpression in the pancreatic cancer cell line Panc-1. Our results point to a main role of TNC in the regulation of the interactions between epithelial cells and ECM in the progression of pancreatic cancer.

Results

Effects of exogenous TNC on pancreatic cancer cell growth

At first, it was tested if TNC added to the culture medium at different concentrations could affect cell viability. An increase in the number of viable Capan-1, AsPC-1 and SU.86.86 cells (up to 25%) at TNC concentration of 0.01–0.1 μg/ml was observed, as measured with the MTT assay after 72 hours of growth in serum free medium (Fig. 1A). Growth of AsPC-1 and Capan-1 was inhibited at the highest TNC concentration (10 μg/ml, 41 and 34% decrease, respectively). TNC had an inhibitory effect on the viability of the Panc-1 and MIA PaCa-2 cell lines (Fig. 1A). Since TNC exerts its function as an ECM-protein, cells were grown on a TNC-rich matrix. When seeded on TNC-coated plates and grown up to 72 hours in serum-free medium, Panc-1 and MIA PaCa-2 showed a 44% and 27% increase in viability, respectively, whereas the growth of Capan-1 and AsPC-1 decreased (23% and 45%, respectively) (Fig 1B).

Exogenous TNC modulates the motility of pancreatic cancer cell lines

In order to test the effect of TNC on the migration of pancreatic cancer cell lines, wound healing assays were performed maintaining the cells in serum free medium in order to minimize cell proliferation. TNC had no effect on the wound closure when added to the growth medium (Fig. 2A). When grown on a TNC-rich matrix, pancreatic cancer cells closed the wound in a dose-dependent way, but each cell line displayed a quite individual response to different concentrations of TNC. In detail, cell migration increased up to 1.7 and 1.1-fold in SU.86.86 and Panc-1 cell lines, respectively, reaching statistical significance at a TNC concentration of 0.5 μg/cm² in SU.86.86 cells and of 0.1 μg/cm² in Panc-1 cells. On the other hand, the wound closure decreased significantly (up to 0.8-fold) in Capan-1 cells with TNC concentrations of 0.5 and 2.5 μg/cm² (Fig. 2B). A TNC concentration of 2.5 μg/cm² had toxic effects on the Panc-1 cells, and the wound healing assay could not be performed under this condition.

Effects of endogenous TNC on cell viability and migration

To give further support to the observed promoting effects of TNC on pancreatic cancer cell growth and motility in the coating procedure, Panc-1 cells were used to generate stable transfectants expressing the large TNC splice variant. Since TNC physiologically acts as an extracellular protein, positive clones were further selected on the basis of their capability to secrete TNC in the culture medium. As shown in figure 3A, the expression levels of secreted TNC were quite different among positive clones. Different expression levels reflected on some of the biological activities of TNC, such as its capability to affect cell viability. In fact, the number of viable cells, as measured with the MTT method after 24, 48 and 72 hours of growth in complete medium, was higher in the TNC-positive clones compared both to the non transfected and to the mock transfected Panc-1 cells (Fig. 3B and C). The strongest effect (compared to the non transfected cells) was observed in the T2 clone, which also showed the highest expression levels of secreted TNC (Fig. 3A and B). In detail, in comparison with non transfected cells, PANC-T2 cells showed an increase in cell viability of 2.06-fold +/−0.01 after 24 hours, of 2.49-fold +/−0.04 after 48 hours and of 3.80-fold +/−0.09 after 72 hours. In PANC-T24 the increase was of 1.21-fold +/−0.01 after 24 hours and of 1.14-fold +/−0.02 after 48 hours, and in PANC-T27 of 1.43-fold +/−0.02 after 24 hours, of 1.32-fold +/−0.03 after 48 hours and 1.08-fold +/−0.05 after 72 hours. The cell viability rates of Panc-1 cells overexpressing TNC compared to the mock transfected cells were 55% higher at 24 hours, 68% higher at 48 hours and 99% higher at 72 hours (Fig. 3C).

Cell migration on the other hand was not influenced by the expression levels of secreted TNC. Stable transfected PANC-T2, PANC-T24 and PANC-T27 cells closed the wound faster than non transfected and mock transfected cells. When compared to the non transfected PANC-1 cells, this effect was significant at 24 hours (1.52-fold +/−0.08) for PANC-T2 and at 48 hours (1.46-fold +/−0.08) for PANC-T27. All positive clones together had a higher migration rate in comparison to the mock transfected clones (62% at 24 hours and 43% at 48 hours, Fig. 3E).

Exogenous TNC stimulates cell adhesion on uncoated plates and reduces cell spreading on FN

As cell adhesion together with migration and invasiveness is a critical step involved in cancer spreading and metastasis, the
adhesion of pancreatic cancer cells on TNC was further investigated. Since TNC overexpression correlates with poor tumor differentiation in vivo [16], we focused our study on the poorly differentiated cell lines PANC-1 and SU.86.86 [18,19]. TNC coating strongly enhanced the adhesion of both cell lines (PANC-1: 7.0-fold, \( p < 0.001 \); SU.86.86: 4.6-fold, \( p < 0.001 \)) as estimated by crystal violet absorbance spectroscopy of attached cells (Fig. 4A, left panel). In the tissue context, cells interact with TNC in combination with other ECM proteins. Among these, FN is often co-expressed with TNC [20]. Therefore, in order to test if TNC modulates cell adhesion in the presence of FN, PANC-1 and SU.86.86 cells were plated on a mixed substrate of FN and TNC. TNC presence determined a significant decrease in the attachment of both cell lines to FN at 3 hours after plating (PANC-1: 1.6-fold, \( p < 0.001 \); SU.86.86: 1.2 fold, \( p = 0.003 \)) (Fig. 4A, left panel). To test if this effect could be due to substrate competition between the two proteins when used together to coat the plastic surface, the substrate binding efficiency of the composite matrix was investigated by ELISA. The binding efficiency of FN or TNC alone was not affected when the plates were coated with both proteins simultaneously, as shown in figure 4B and C. Cell viability was also not significantly affected when cells were grown onto FN/ TNC coated plates compared with FN coated plates (MTT assay, data not shown). Taken together, these results show that TNC interferes with cell adhesion on FN, but it has an opposite effect on uncoated plates.

**TNC and FN influence paxillin and Akt activation by phosphorylation**

In order to investigate the pathways involved in the adhesive behavior of pancreatic cancer cells on TNC and/or on FN substrates, the phosphorylation level of paxillin at Tyr 118, an early step in integrin mediated signaling, as well as the phosphorylation level of Akt at Ser 473 and the expression levels of vinculin, a protein involved in the connection of focal adhesions to the actin cytoskeleton, were analyzed by immunoblotting.
As shown in Fig. 4, TNC and FN had a slight enhancing effect on the phosphorylation state of Akt in the PANC-1 and SU.86.86 cell lines during the first steps of cell adhesion (45 min). This effect was not evident anymore after 24 hours and at later time points (not shown). As for cell adhesion, TNC seemed to have opposite effects depending on the experimental set up. In fact phospho-Akt was slightly up-regulated when comparing TNC coated plates vs uncoated plates and down-regulated when comparing FN/TNC.
Figure 4. Effect of TNC, FN, and FN/TNC coating on the adhesion of PANC-1 and SU.86.86 cell lines. (A) Cells were plated in medium containing 1% FBS, incubated for 3 hours and fixed. For pharmacological inhibition, cells were incubated with AZD0530 2 μM for 15 min before plating. Left panel: TNC enhances cell adhesion compared to uncoated plates and decreases cell attachment to FN. Right panel: When treated with AZD0530, cells displayed a reduced adhesion compared to the non treated cells at all conditions tested. Data are calculated as mean ± s.e.m of two experiments and expressed as fold-change compared to the control (Ctrl) or to the untreated cells (*p<0.01, **p<0.001, ANOVA test). (B, C) 96-well plates were coated with TNC (0.5 μg/cm²), FN (1 μg/cm²) or both proteins simultaneously (FN/TNC) and ELISA was performed as described in Methods. The substrate binding activity of TNC or FN is not affected when both proteins are used to coat the plastic surface. (D, E) PANC-1 (D) and SU.86.86 cells (E) were plated for 45 min before total protein extraction was performed. Phosphorylation of paxillin at Tyr 118 (pPAX) and of Akt at Ser 473 (pAKT), and total paxillin and Akt expression levels were investigated by immunoblotting using specific antibodies and after treating the cells with the Src kinase inhibitor AZD0530. GAPDH detection was used to confirm equal protein loading.
doi:10.1371/journal.pone.0021684.g004
coated plates vs FN coated plates. The same trend could be seen when measuring paxillin activation, while vinculin levels were not affected either by TNC or FN (not shown). The Src kinase inhibitor AZD0530 (Saracatinib), which inhibits the phosphorylation of paxillin and Akt, was used to confirm that the observed effects on cell adhesion were actually mediated by molecules of the integrin signaling pathway. In adhesion experiments, after incubation with AZD0530 an inhibition of paxillin and Akt phosphorylation was observed (Fig. 4D and E). This effect was accompanied by a significant decrease in PANC-1 and SU.86.86 adhesion at all conditions tested (PANC-1 FN: p = 0.004; all other conditions p < 0.001), with the exception of SU.86.86 adhesion to uncoated plates (Fig. 4A, right panel).

Next, TNC effect on focal adhesion assembly was investigated on a morphological level by immunofluorescence. As shown in Fig. 5, PANC-1 cells grown for 45 min on a TNC coated surface showed a more diffuse co-localization pattern of vinculin and phospho-paxillin than that observed on the uncoated surface, where focal adhesions appeared more elongated and mainly concentrated at the periphery of the spreading cell. On a FN matrix, only slightly noticeable differences in phospho-paxillin and vinculin distribution between cells adhered on FN and FN/TNC were observed. In both cases, phospho-paxillin/vinculin areas were mainly restricted to the periphery of the adhering cells, with longer and more dispersed adhesion sites in the presence of TNC.

Discussion

PDAC is characterized by a prominent increase in the connective tissue that surrounds cancer cells. Major contributors to this so-called “desmoplastic” reaction are PSCs, a subpopulation of pancreatic cells that, once activated by growth factors, cytokines and oxidative stress, secrete excess amounts of ECM proteins and soluble mediators establishing a cross-talk with tumor cells. Several lines of evidence suggest that the desmoplastic microenvironment plays a key role in regulating the rapid growth and invasion of pancreatic cancer, angiogenesis and resistance to chemotherapy [4–7,21–26].

TNC is a large stromal ECM protein that is up-regulated in the progression from PanINs to PDAC [17] and its expression has been correlated with a poorly differentiated phenotype of PDAC [16]. Moreover, TNC expression has been correlated with a poor prognosis of patients affected by lung and brain cancer [21,27–29], whereas no correlation between expression levels and prognosis has been found in pancreatic cancer [16]. TNC is able to interact with several ECM proteins (such as FN, perlecan, aggrecan, versican and brevican) and many cell-surface receptors (including integrins α2β1, α7β1, α9β1, αvβ3, annexin II, EGFR and syndecan 4), modulating cellular signaling and influencing cell migration and proliferation [11]. Additionally, in the adult organism TNC has adhesive and anti-adhesive properties and is expressed during physiological and pathological conditions where cell migration and tissue remodeling is involved, like in the wound healing process or during tumorigenesis and metastasis [11]. However, the molecular mechanisms by which TNC influences cancer progression are still largely unknown. To address this question in PDAC, we have investigated how TNC affects biologic relevant properties of pancreatic cancer cells.

The results presented here demonstrate that TNC is able to support and promote growth and migration of poorly differentiated pancreatic cancer cell lines. Another interesting observation is that TNC alone shows a pro-adhesive effect on pancreatic cancer cells, in contrast to the reported anti-adhesive effect in the majority of other studied cell lines, like glioblastoma and breast carcinoma cells [22]. This pro-adhesive effect on pancreatic cancer cells is associated with an increase in the phosphorylation state of Akt and to a lesser extent of paxillin. This suggests a mechanism involving integrin-mediated adhesion to TNC, in analogy to what has been
previously demonstrated in chondrosarcoma cells, where an increase of Ser 473 phosphorylation of Akt in cells adhering to TNC promotes cell survival in serum deprived medium [23]. However, the effects of TNC on pancreatic cancer cell viability and proliferation were quite heterogeneous and an inhibition of proliferation were quite heterogeneous and an inhibition of cell proliferation on a FN substrate are not general but strictly dependent on the specific cell line and on the experimental set up [26]. Moreover, opposite adhesive and migratory responses to TNC in the same glioma cell line depending on the integrin receptor involved [30] and different adhesive responses mediated by the same integrin in different cell lines [31] have been described. Interestingly, on a FN coated surface TNC decreases pancreatic cancer cell adhesion and phospho-paxillin and phospho-Akt levels. This effect on a mixed TNC-FN matrix, which closely resembles the in vivo situation, where TNC and FN interact in the tumor-associated ECM, has already been described for glioblastoma and breast carcinoma cells [20,22]. In these tumors, TNC reduces cell spreading on FN interfering with FN binding to the integron-co receptor syndecan-4, thus compromising focal contact and stress fiber formation [29]. Since the substrate binding efficiency of FN was not affected by TNC in our study, as assessed by ELISA, a similar mechanism of competition for cell surface receptors can be hypothesized in PDAC cells. Due to this effect, activation of paxillin and focal adhesion kinase (FAK) and, consequently, actin stress fiber and focal contact formation as well as full cell spreading is inhibited, with an overall enhancement in cell proliferation [22]. Weak binding to FN usually correlates with an enhanced proliferation in many tumor cells [32]. In our experimental set up, we did not observe an increase in cell proliferation for PANC-1 and SU.86.86 cells on a mixed substrate of FN and TNC compared to FN alone, probably because the effects of TNC on adhesion were limited to short times (3 hours) and focal adhesion assembly in the FN-adherent cells was only slightly altered by TNC, as observed by immunofluorescence. These observations suggest that the mechanisms by which TNC influences cancer cell adhesion and proliferation on a FN substrate are not general but strictly dependent on the specific cell line and on the experimental set up used.

It is known that the ability of cancer cells to interact with extracellular matrix proteins, like FN, is crucial for cell invasion and migration. Our data show that the number of pancreatic cancer cells that adhere to FN at short times is decreased in the presence of TNC but is still high and in the range of the number of cells adhering to TNC alone. TNC may therefore act as a modulator of early migratory events, which include substrate sensing and adhesion, and may promote cell migration by reducing cell adhesiveness to FN, thus inducing a more dynamic interaction between the tumor cell and the ECM components. Further work is needed to understand how TNC affects the adhesion process during pancreatic cancer cell interaction with FN, which cell receptors are involved and which additional intracellular pathways may be altered.

In conclusion, the present data show that TNC affects growth, motility and adhesion of pancreatic cancer cells, these effects being divergent depending on cell differentiation and on the composition of the extracellular matrix. Therapeutic strategies aiming at disrupting the TNC-rich matrix might be therefore helpful in contrasting the extraordinary aggressiveness of PDAC.

**Materials and Methods**

### Maintenance of cell lines

Pancreatic cells of lines Capan-1, AsPC-1, PANC-1, MIA PaCa-2 and SU.86.86 [18,19,33] (American Type Culture Collection, ATCC) were maintained in high glucose DMEM media containing 10% fetal bovine serum (FBS), and 1 X Penicilline/Streptomomicne (Invitrogen, Carlsbad, CA) at 37 °C in a humified atmosphere with 5% CO2. Cells were tested for mycoplasma contamination by polymerase chain reaction (TA-KARA, Shiga, Japan).

### Generation of stable clones overexpressing TNC

The plasmid TNC-L, in which the large, unspliced isoform of TNC is cloned into a pCMV-Script vector (Stratagene, La Jolla, CA, USA), was a generous gift from Dr. JH Pringle (Department of Cancer Studies & Molecular Medicine, University of Leicester School of Medicine, UK) [34]. The complete TNC-L coding sequence was checked by sequencing. Then, the TNC-L plasmid and the empty vector pCMV-Script were first linearized with the restriction enzyme APA-L1 and then transfected into the PANC-1 cancer cells using the FuGENE transfection reagent (Roche Diagnostics, Mannheim, Germany), according to the manufacturer’s instructions. After 2 days, cells were subjected to G418 selection at a concentration of 1 mg/ml. After 2 weeks in the presence of G418, several colonies were observed and amplified. Colonies were checked for the presence of the transfected gene by PCR assay using the primers 5-CGTTGACGTTGGGAAGGTCTA-3 (on pCMV-Script) and 5-CACTGCTTCGAGTCGC-3 (in the TNC gene). The capability of PCR-positive colonies to secrete TNC was confirmed by Western blotting. The positive clones PANC-T2, PANC-T24, PANC-T27 and the control (mock transfected) clones PANC-C21, PANC-C23, PANC-C27 were selected for the following experiments.

### TNC and FN coating

TNC was purchased from Millipore (Millipore GmbH, Schwabach, Germany) and FN from Biochrom (Berlin, Germany). For 96-well plates (viability and adhesion), coating was performed with TNC at a final concentration of 1 μg/cm2. For 24-well plates (wound healing assays) TNC concentrations of 0.1 μg/cm2, 0.5 μg/cm2 and 2.5 μg/cm2 were used. For 6-well plates (immunoblotting) a concentration of 0.5 μg/cm2 was used. FN coating was performed with a final concentration of 2 μg/cm2 for 96-well plates and 1 μg/cm2 for 24- and 6-well plates. Coating proteins were allowed to be adsorbed overnight at 4 °C, wells were then washed with PBS to remove unbound proteins and blocked for 30 min at 37 °C by the addition of 0.2% heat-denatured (85 °C for 12 min) BSA in PBS. Plates were finally washed twice with sterile PBS and sterilized by UV exposure for 20 min. Coverslips used in immunofluorescence experiments were placed into 24-multi-well plates and coated in the same way. Mixed substrates of TNC and FN were prepared by coating with both proteins simultaneously. Uncoated plates, blocked with BSA, are referred in this manuscript as “uncoated”.

### Growth assay

Cells were seeded into 96-multi-well plates (Nunc GmbH & Co. KG, Langenselbold, Germany) at a density of 20,000/cm2 and in medium containing 10% FBS. After 24 hours the medium was changed with serum free medium containing different concentrations of TNC (0.01, 0.1, 1 and 10 μg/ml). Cells were then grown for 72 hours before 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylhete-
zolium bromide (MTT) assay was performed as previously described [35]. To test the effect of TNC coating, cells from 70–80% confluent cultures were seeded into 96-multi-well plates at a density of 20,000/cm² in serum-free medium. Cells were then grown up to 72 hours and MTT assay was performed. For experiments with stably transfected PANC-1, cells were seeded into 96-multi-well plates at a density of 10,000/cm² and in medium containing 10% FBS. Cells were then grown up to 72 hours and MTT assay was performed at different time points (24, 48 and 72 hours).

### Adhesion assay

Cells were trypsinized, resuspended to a concentration of 300,000/ml in medium with 1% FBS and incubated 20 min at 37°C, 5% CO₂. For experiment with the Src kinase inhibitor AZD0530 (Saracatinib), cells were further incubated with the drug (2 µM) for 15 min. Then, 50 µl (15,000 cells) were plated onto 96-multi-well plates, whose wells had been filled with 50 µl medium containing 1% FBS and equilibrated at 37°C, 5% CO₂ for 1 hour. After 3–24 hours of incubation, medium was aspirated and the wells were washed twice with PBS to remove non-adherent cells. Cells were then fixed with 5% glutaraldehyde in PBS for 20 min and stained for 60 min with a filtered solution of 0.1% (w/v) crystal violet in 200 mM 2-(N-morpholino)ethanesulfonic acid (MES), pH 6.0. Cells were washed four times with water, air-dried and lysed in 100 µl of 10% (v/v) acetic acid in water. Absorption was measured at 560 nm using an ELISA reader. Six-well plates were used for protein extraction. Both adherent and non-adherent cells were collected after 45 min–72 hours of incubation.

### Wound healing assay

Cells were plated onto 24-multi-well plates and after 24 hours the monolayer was scraped with a 10 µl pipette tip. After three washes with PBS, cells were incubated at 37°C, 5% CO₂, in serum free medium with different TNC concentrations (0.2 µg/ml, 1 µg/ml and 5 µg/ml) or without TNC. To test the effect of TNC coating, the same procedure was performed on TNC-coated 24-multi-well plates (0.1 µg/cm², 0.5 µg/cm² and 2.5 µg/cm² TNC, respectively). In both cases, the migration of cells into wounded areas was evaluated at the indicated times by taking images with a Zeiss Axiosvert microscope coupled with a digital camera (AxioCam Icc3, Carl Zeiss Vision GmbH, Jena, Germany) and counting migrated cells manually. A total of 2–4 fields were counted per group in each experiment.

For experiments with stably transfected cells, cells were plated onto 24-multi-well plates at a density of 75,000 cells/cm² and, after 6 hours, medium was changed and cells were maintained overnight in medium containing 0.1% FBS. The monolayer was then scraped with a 10 µl pipette tip. After three washes with PBS, cells were incubated at 37°C, 5% CO₂, in medium containing 0.1% FBS. Images were taken at the indicated times with an Evos XL microscope (AMG - Advanced Microscopy Group, Bothell, WA, USA) and cell migration into wounded areas was evaluated using TScratch software [36]. A total of 4–8 fields were counted per group in each experiment.

### Whole cell extract and supernatant preparation

Culture medium was removed and not attached cells were collected by centrifugation. Cell monolayers were rinsed twice with cold PBS. Both pelleted and still adherent cells were lysed in cold lysis buffer (20 mM Tris, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1 mM EDTA, 1 mM EGTA pH 7.4) supplemented with protease and phosphatase inhibitor cocktails (Roche Diagnostics, Mannheim, Germany). Cell lysates were passed through a 26G needle several times and cellular debris was removed by centrifugation at 15000 x g for 10 min at 4°C. The protein concentration in the soluble fractions was determined using the BCA protein assay kit (Thermo Scientific, Schwerte, Germany) and the extracts were aliquoted and stored at −80°C. Transfected cell lines were grown in culture medium for 72 hours until cells reached 80% confluence. 250 µl of the supernatant were then taken and precipitated with 4 vol acetone over night at −20°C. The precipitate was centrifuged 20 min at 13,000 rpm and resuspended in 2X Laemmli buffer.

### Immunoblot analysis

Cell lysates were subjected to SDS-PAGE with 5%, 10% or 12% polyacrylamide gels using the Mini-PROTEAN Tetra cell apparatus (Bio-Rad Laboratories GmbH, Munich, Germany) at 110 V for 1 hour in Tris–glycine buffer (25 mM Tris, 250 mM Glycine, 0.1% SDS, pH 8.3). Resolved proteins were transferred from the gels to nitrocellulose membranes using a Mini Trans-Blot Cell electrophoretic transfer cell (Bio-Rad) at 120 V in transfer buffer (48 mM Tris, 39 mM Glycine, 0.025% SDS, 20% Methanol, pH 8.3). Non-specific antibody binding was blocked by incubation of the membranes in 5% BSA in TTBS buffer (20 mM Tris, 136 mM NaCl, 0.1% Tween20, pH 6.8), for 1 hour at room temperature. The membranes were then incubated overnight at 4°C with antibodies anti-phospho-paxillin (Tyr 118, 1:1000, GeneTex Inc.), anti-paxillin (1:500, Cell Signaling), anti-GAPDH (1:1000, Santa Cruz Biotechnology), anti-vinculin (1:200) was performed in the blocking solution at RT in a humidified chamber overnight. After washing three times with TTBS, slides were incubated with Alexa Fluor 488 goat anti-mouse-IgG or Alexa Fluor 647 goat anti-rabbit-IgG (1:200, Invitrogen), anti-vinculin (1:200) was performed in the blocking solution at RT in a humidified chamber overnight. After washing three times with TTBS, cells were incubated with Alexa Fluor 488 goat anti-mouse-IgG or Alexa Fluor 647 goat anti-rabbit-IgG (1:200, Invitrogen GmbH, Karlsruhe, Germany) in blocking solution for 1 hour. Slides were then washed again three times with TTBS. All steps were performed under gentle agitation on a rotary shaker. The signals were visualized using the Super Signal West Pico Chemiluminescent Kit (Thermo Scientific, Schwerte, Germany) and by light-sensitive imaging film (Amersham Hyperfilm ECL, GE Healthcare, Munich, Germany).

### Immunofluorescence

Cells adhering to coverslips were washed with PBS, fixed with 4% formaldehyde in PBS buffer for 15 min at RT, washed three times with TBS (50 mM Tris, 138 mM NaCl, 2.7 mM KCl, pH 7.6), permeabilized with Triton X-100 (0.25% v/v in TBS) for 5 min, before being washed twice and blocked for 1 hour in blocking solution (TBS containing 10% goat serum and 0.1% Triton X-100). Then, incubation with antibodies anti-phospho-paxillin (Tyr 118, 1:100, Santa Cruz Biotechnology, CA) and anti-vinculin (1:200) was performed in the blocking solution at RT in a humidified chamber overnight. After washing three times with TBS, slides were incubated with Alexa Fluor 488 goat anti-mouse-IgG or Alexa Fluor 647 goat anti-rabbit-IgG (1:200, Invitrogen GmbH, Karlsruhe, Germany) in blocking solution for 1 hour. Slides were then washed again three times before being counterstained with Hoechst 33342 (0.2 µg/ml in water) for 5 min, briefly washed with TBS, covered with anti-fade mounting medium (Vectorshied, Loerrach, Germany) and placed onto microscope slides. Slides were examined under a Zeiss Axiosvert fluorescent microscope (Carl Zeiss AG, Germany). Negative controls were performed omitting the primary antibodies.
ELISA

96-well plates were coated with TNC (0.5 μg/cm2), FN (1 μg/cm2) or both proteins simultaneously (FN/TNC). A calibration curve was generated using FN at a density between 125 ng/cm2 and 2 μg/cm2 and TNC at a density between 62.5 ng/cm2 and 1 μg/cm2 to coat the plate. The amount of FN or TNC on the plate was then quantified by the ELISA assay (JBL International GmbH, Hamburg, Germany) according to the manufacturer’s instructions.

Statistical analysis

Means were compared using the Students t-test or the one-way analysis of variance (ANOVA) with the package S-PLUS (Tibco, Palo Alto, CA). Data are presented as mean ± SEM (standard error of the mean).

References

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225–249.
2. Baxter NN, Whitson BA, Tuttle TM (2007) Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol 14: 1320–1326.
3. Rivera F, Lopez-Tarruella S, Vega-Villegas ME, Salcedo M (2009) Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev 35: 335–339.
4. Vonlaufen A, Joshi S, Qu C, Phillips PA, Xu Z, et al. (2008) Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res 68: 2085–2093.
5. Bachem MG, Schumann M, Ramadani M, Stech M, Beger H, et al. (2005) Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128: 907–921.
6. Omary MB, Luga A, Lowe AW, Pandol SF (2007) The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest 117: 50–59.
7. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, et al. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy to a mouse model of pancreatic cancer. Science 328: 1457–1461.
8. Pas J, Wysock E, Rolly K, Rychelevski L, Nowak S, et al. (2006) Analysis of structure and function of tenascin-C. Int J Biochem Cell Biol 38: 1594–1602.
9. Jones FS, Jones PL (2000) The tenasin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 218: 233–259.
10. Fischer D, Tucker RP, Chiquet-Ehrismann R, Adams JC (1997) Cell-adhesive responses to tenasin-C splice variants involve formation of fascin microspikes. Mol Biol Cell 8: 2055–2073.
11. Midwood KS, Orend G (2005) The role of tenasin-C in tissue injury and tumorigenesis. J Cell Commun Signal.
12. Koukoulis GK, Gould VE, Bhattacharyya A, Gould JE, Howeedy AA, et al. (1991) Tenasin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. Hum Pathol 22: 636–643.
13. Erickson HP, Bourdon MA (1989) Tenascin: an extracellular matrix protein prominent in embryonic tissues and tumors. Annu Rev Cell Biol 5: 71–92.
14. Chiquet-Ehrismann R, Chiquet M (2003) Tenascins: regulation and putative functions during pathological stress. J Pathol 200: 488–499.
15. Orend G (2005) Potential oncogenic action of tenasin-C in tumorigenesis. Int J Biochem Cell Biol 37: 1066–1083.
16. Juuti A, Nordling S, Louhim J, Lundin J, Haglund C (2004) Tenasin C expression is upregulated in pancreatic cancer and correlates with differentiation. J Clin Pathol 57: 1151–1155.
17. Esposito I, Penzel R, Chaib-Harrireche M, Barcena U, Bergmann F, et al. (2006) Tenasin C, and annexin II expression in the process of pancreatic carcinogenesis. J Pathol 208: 673–685.
18. Drucker BJ, Marincola FM, Saso DY, Donlon TA, Bangs CD, et al. (1989) A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice. In Vitro Cell Dev Biol 24: 1179–1187.
19. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, et al. (2003) A comprehensive characterization of pancreatic ductal carcinoma cell lines towards the establishment of an in vitro research platform. Virochows Arch 442: 444–452.
20. Chiquet-Ehrismann R, Kalla P, Pearson CA, Beck K, Chiquet M (1988) Tenasin interferes with fibronectin action. Cell 53: 383–389.
21. Ishiwata T, Takahashi K, Shimanski Y, Ohtsuki R, Cui R, et al. (2005) Serum tenasin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Res 25: 419–495.
22. Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A, Orend G (2001) Interference of tenasin-C with syndecan-1 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res 61: 8596–8594.
23. Jang JH, Chung CP (2005) Tenasin-C promotes cell survival by activation of Akt in human chondrosarcoma cell. Cancer Lett 229: 101–105.
24. End P, Panayotou G, Entwisle A, Waterfield MD, Chiquet M (1992) Tenasin: a modulator of cell growth. Eur J Biochem 209: 1041–1051.
25. Crossin KL (1991) Cytostatin binding: inhibition of stimulated proliferation and intracellular alkalization in fibroblasts. Proc Natl Acad Sci U S A 88: 11403–11407.
26. Erickson HP (1993) Tenasin-C, tenasin-R and tenasin-X: a family of talented proteins in search of functions. Curr Opin Cell Biol 5: 869–876.
27. Kaarteenaho-Wiik R, Soini Y, Pollanen R, Paakko P, Kinnula VL (2003) Over-expression of tenasin-C in malignant pleural mesothelioma. Histopathology 42: 280–289.
28. Leins A, Riva P, Lindstedt R, Davidov MS, Mehraein P, et al. (2003) Expression of tenasin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 98: 2430–2439.
29. Zanencik J, Chanova M, Tichy M, Kodet R (2004) Distribution of the extracellular matrix glycoproteins in ependymomas—an immunohistochemical study with follow-up analysis. Neoplasma 51: 214–222.
30. Giese A, Loo MA, Norman SA, Treasurywala S, Berens ME (1996) Contrasting migratory response of astrocytoma cells to tenasin mediated by different integrins. J Cell Sci 109 (Pt 8): 2161–2168.
31. Sriramarao P, Mendler M, Bourdon MA (1993) expression of tenascin-C in malignant pleural mesothelioma. Histopathology 42: 280–289.
32. Giancotti FG, Ruoslahti E (1990) Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 60: 849–859.
33. Moore PS, Sipos B, Orlandini S, Sorci C, Real FX, et al. (2001) Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virochows Arch 439: 798–802.
34. Hancos RA, Allen MD, Holiday DL, Edwarth DR, Pennington CJ, et al. (2009) Tumour-associated tenasin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 11: R24.
35. Esposito I, Kayed H, Keleg S, Giese T, Sage EH, et al. (2007) Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia 9: 8–17.
36. Geback T, Schulz MM, Koumoutsakos P, Demtar M (2009) TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques 46: 265–274.